Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Novel therapies for psoriasis.

Jennifer Cather1, Alan Menter

  • 1Baylor University Medical Center, Dallas, Texas, USA. research@texasderm.com

American Journal of Clinical Dermatology
|April 30, 2002
PubMed
Summary

Psoriasis treatment is shifting towards targeted therapies, focusing on T lymphocytes to reduce organ toxicity. New biologic drugs offer promising, safer alternatives for moderate to severe psoriasis management.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Considerations for Genital Psoriasis Care Across Age Groups: A Modified Delphi Consensus Initiative from the Genital Psoriasis Wellness Consortium.

American journal of clinical dermatology·2026
Same author

Clarifying psoriasis disease severity: A position statement from the National Psoriasis Foundation Medical Board.

Journal of the American Academy of Dermatology·2026
Same author

Efficacy of long-term risankizumab treatment for moderate-to-severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial).

Journal of the European Academy of Dermatology and Venereology : JEADV·2024
Same author

Summary of Research: Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial.

Dermatology and therapy·2023
Same author

Response to letter to the editor "It's time to consider a new topical algorithm for psoriasis".

Journal of the American Academy of Dermatology·2023
Same author

A Review of Phase 3 Trials of Dupilumab for the Treatment of Atopic Dermatitis in Adults, Adolescents, and Children Aged 6 and Up.

Dermatology and therapy·2022

Area of Science:

  • Dermatology
  • Immunology
  • Pharmacology

Background:

  • Psoriasis pathogenesis is primarily T cell-driven, with keratinocytes playing a secondary role.
  • Traditional treatments like topical corticosteroids and systemic methotrexate or cyclosporine have limitations including organ toxicity.
  • Acitretin is less effective as monotherapy but can be combined with phototherapy.

Purpose of the Study:

  • To review the evolution of psoriasis treatment, focusing on systemic therapies.
  • To highlight the limitations of current systemic treatments and the need for targeted therapies.
  • To discuss the development and potential of new biologic agents for psoriasis.

Main Methods:

  • Review of existing literature on psoriasis pathogenesis and treatment.
  • Analysis of approved systemic medications (cyclosporine, methotrexate, acitretin) and their toxicities.
  • Evaluation of emerging biologic therapies and other treatment modalities.

Main Results:

  • Biologic drugs target T lymphocytes, offering potential for long-term disease control with reduced organ toxicity.
  • While not all biologics match methotrexate or cyclosporine efficacy, they show promise for intermittent use and safer profiles.
  • Adverse effects of biologics are generally mild, with infection rates comparable to placebo.

Conclusions:

  • Targeting T lymphocytes represents a significant advancement in psoriasis treatment.
  • Biologic therapies offer a safer and potentially more effective long-term management strategy for moderate to severe psoriasis.
  • The future of psoriasis treatment is bright with ongoing research into targeted and novel therapeutic approaches.

Related Experiment Videos